Last checked at 8 Feb 2017 07:00
8 February 2017
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Notice of Interim Results
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, will be announcing its interim results for the half year ended 30 November 2016 on Friday 10 February 2017.
Geoffrey Hamilton-Fairley, Chief Executive Officer, and Andrew Millet, Chief Financial Officer, will hold a conference call for analysts, followed by a Q&A session, at 10.00am on the day of the results.
To access the conference call, please use the following dial in details:
Tel: +44 (0) 2071 928000
Conference ID: 69040765
The presentation will be made available on the Investors section of the Oncimmune website shortly before the call and can be accessed at: http://oncimmune.com/investors/results-reports-presentations/
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled start time.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
About Oncimmune
Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.
Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com